RxSight, Inc. Announces Proposed Public Offering of Common Stock
February 07 2023 - 3:05PM
(NASDAQ: RXST) – RxSight, Inc.,
an ophthalmic medical device company dedicated to improving the
vision of patients following cataract surgery, announced today that
it intends to offer and sell, subject to market and other
conditions, $40.0 million of shares of its common stock in an
underwritten public offering. In
addition, RxSight expects to grant the underwriters a
30-day option to purchase up to an additional 15% of the shares of
common stock offered in the offering on the same terms and
conditions. RxSight intends to use the net proceeds of
the offering for continued commercial and marketing expansion,
funding of product development, research and clinical development,
and for working capital and general corporate purposes. All of the
shares are being offered by RxSight. There can be no assurance
as to whether or when the offering may be completed, or the actual
size or terms of the offering. BofA Securities is acting as the
sole bookrunning manager for the offering.
A shelf registration statement on Form S-3 relating to the
common stock offered in the public offering described above was
filed with the Securities and Exchange Commission (SEC) on August
8, 2022 and declared effective by the SEC on August 12, 2022. The
proposed offering is being made only by means of a prospectus
supplement and accompanying prospectus that form a part of the
registration statement. A preliminary prospectus supplement and
accompanying prospectus relating to the offering will be filed with
the SEC and will be available on the SEC’s website at www.sec.gov.
Copies of the preliminary prospectus supplement and accompanying
prospectus relating to the offering, when available, may also be
obtained from BofA Securities, Attention: Prospectus Department,
NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC
28255-0001, by telephone at 1-800-294-1322 or by email at
dg.prospectus_requests@bofa.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
shall there be any sale of the securities being offered in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About RxSight, Inc.RxSight, Inc. is a
commercial-stage medical technology company dedicated to improving
the vision of patients following cataract surgery. The RxSight®
Light Adjustable Lens system, comprised of the RxSight Light
Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and
accessories, is the first and only commercially available
intraocular lens (IOL) technology that enables doctors to customize
and optimize visual acuity for patients after cataract surgery.
Forward-Looking StatementsThis press release
contains forward-looking statements, including statements
concerning expectations with respect to the completion, timing and
size of the proposed public offering, the grant to the underwriters
of an option to purchase additional shares and the anticipated use
of the net proceeds from the proposed offering. Risks and
uncertainties related to these endeavors include, but are not
limited to, risks and uncertainties associated with market
conditions and the satisfaction of customary closing conditions
related to the proposed public offering. Investors should review
the risks and uncertainties contained in our filings with the
Securities and Exchange Commission (“SEC”), including our Quarterly
Report on Form 10-Q for the quarter ended September 30, 2022, filed
with the SEC on November 7, 2022, in the preliminary prospectus
supplement related to the proposed public offering to be filed with
the SEC, as well as other risks set forth in our other filings with
the SEC. We caution you that the forward-looking information
presented in this press release is not a guarantee of future
events, and that actual events may differ materially from those
described in or suggested by the forward-looking information
contained in this press release. In addition, forward-looking
statements generally can be identified by the use of
forward-looking terminology such as “may,” “will,” “should,”
“could,” “would,” “expects,” “plans,” “intends,” “anticipates,”
“believes,” “estimates,” “predicts,” “projects,” “potential,” or
“continue” or the negative of such terms and other similar
terminology. Any forward-looking information presented herein is
made only as of the date of this press release, and we do not
undertake any obligation to update or revise any forward-looking
information to reflect changes in assumptions, the occurrence of
unanticipated events, or otherwise.
Company Contact:Shelley B. ThunenChief
Financial Officersthunen@rxsight.com
Investor Relations Contact:ir@rxsight.com
RxSight (NASDAQ:RXST)
Historical Stock Chart
From Jun 2024 to Jul 2024
RxSight (NASDAQ:RXST)
Historical Stock Chart
From Jul 2023 to Jul 2024